Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Tumor resection.
- Who it may be relevant to
- Registry conditions: Estrogen Receptor Positive Breast Cancer. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Tn-Miner: Technology for the Discovery of Tumor-specific Glycopeptide Immunotherapy Targets.
Overview
The goal of this interventional, prospective research on human bodily material is to discover new, cancer-specific molecular structures (i.e. glycopeptides) within surgically removed, estrogen receptor positive breast cancer tumors. The main goal it aims to achieve is: To discover tumor-specific targets, that allow the use of very potent immunotherapeutic drugs as treatment for solid tumors, such as estrogen receptor positive breast cancer. These new targets are very specific for cancer cells, meaning that virtually no healthy cells should be attacked by the treatment, resulting in less side effects. Participants will undergo standard of care treatment, comprising surgical removal of the breast tumor. Part of these tissues will be used for this clinical research.
Interventions
- Procedure Tumor resection
As the standard of care, estrogen receptor-positive breast tumors are surgically resected. From these resected tumors, small samples of both cancer tissue and healthy surrounding tissue will be analyzed using our patented Tn-Miner workflow to discover novel tumor-specific epitopes.
Primary outcome measures
- Discovery of new, tumor-specific, glycopeptide epitopes. [Time frame: The patients are only involved during their standard of care surgery (one day). The discovered epitopes will not be shared with enrolled patients.]
Eligibility criteria
Inclusion criteria
- Female
- Minimally 18 years old
- Diagnosed with estrogen-receptor positive breast cancer
- This must be a primary tumor
Exclusion criteria
- Male
- Younger than 18 years old
- Previous history of other tumors
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
Belgium · 2 centers
- AZ Maria Middelares — Ghent
- University Hospital Ghent — Ghent
Identifiers
NCT: NCT06629233 · ONZ-2023-0589 · F2022/IOF-StarTT/089